Interleukin 12/23 inhibitors
Another type of biological therapy is Interleukin 12/23 inhibitors. The mechanism of action of Interleukin 12/23 inhibitors is complex. The drug binds to the interleukin 12 and 23 proteins and inhibits their action, reducing inflammatory cytokine production. This inhibition helps reduce the joint swelling, pain, and stiffness associated with psoriatic arthritis. In addition, the drug has been shown to reduce the progression of the disease and improve overall joint function.
Interleukin 12/23 inhibitors have been well studied in clinical trials and have been found to be effective in treating psoriatic arthritis. The drugs have a good safety profile, with few severe side effects observed. They are also well tolerated, with most people experiencing no adverse reactions.